Premier Biomedical, Inc. (BIEL) Posts Favorable Phase 1 Clinical Trial for Breast Cancer Treatment
Premier Biomedical has released the results of a completed phase 1 mouse testing of its breast cancer therapy, with results demonstrating the methodology’s ability to outperform chemotherapy with a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded 19 days after first treatment. Twenty-five days into the study, the mice administered Premier Biomedical's treatment experienced a 100 percent survival rate without encountering a single cancer-related fatality. This is compared to a mortality rate of nearly one-third of the mice subjected to chemotherapy. In addition, the tumors of the mice given Premier Biomedical's treatment shrunk in size…